Gentamicin for Junctional Epidermolysis Bullosa
![]() |
The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Know the risks and potential benefits of clinical studies and talk to your health care provider before participating. Read our disclaimer for details. |
ClinicalTrials.gov Identifier: NCT03526159 |
Recruitment Status :
Recruiting
First Posted : May 16, 2018
Last Update Posted : April 7, 2020
|
- Study Details
- Tabular View
- Results Submitted
- Disclaimer
- How to Read a Study Record
Condition or disease | Intervention/treatment | Phase |
---|---|---|
Junctional Epidermolysis Bullosa | Drug: Gentamicin Sulfate | Phase 1 Phase 2 |
Three subjects (adults and children of any age) will receive topical gentamicin to be applied to select skin sites.
Three subjects (adults and children of any age) will receive intravenous (IV) gentamicin infusions.
Patients will be assessed for Primary and Secondary endpoints during follow up visits.
Study Type : | Interventional (Clinical Trial) |
Estimated Enrollment : | 6 participants |
Allocation: | N/A |
Intervention Model: | Single Group Assignment |
Masking: | None (Open Label) |
Primary Purpose: | Treatment |
Official Title: | A Pilot Study of the Restoration of Functional Laminin 332 in JEB Patients With Nonsense Mutations After Topical and Intravenous Gentamicin Treatment |
Actual Study Start Date : | June 1, 2018 |
Estimated Primary Completion Date : | July 30, 2020 |
Estimated Study Completion Date : | August 31, 2020 |

Arm | Intervention/treatment |
---|---|
Experimental: Gentamicin Sulfate
IV Arm: 7.5 mg/kg gentamicin once daily for 14 days. Topical Arm: 0.5% gentamicin ointment applied twice daily for 14 days to selected skin sites. |
Drug: Gentamicin Sulfate
Gentamicin (formulated as gentamicin sulfate) is a well-known, well-characterized antibiotic that has been used for four decades as a treatment against gram negative bacteria. It, like other aminoglycoside antibiotics, has the well documented added potential to facilitate readthrough of premature termination codons in eukaryotic cells and organisms.
Other Name: Gentamicin |
- Increased laminin beta 3 / laminin 332 expression as assessed by immunofluorescence. [ Time Frame: 3 months ]New or increased staining of the target protein, laminin 332, in sections of skin biopsies obtained during follow-up visits in comparison with baseline biopsies. Five micron cryosections will be probed with three different antibodies against laminin 332. Patient samples along with normal control samples will be compared. Mean fluorescence intensity will be calculated for each sample and antibody using ImageJ software. Percent expression relative to normal human skin (set to 100%) will be calculated for each patient sample. Any statistically significant increase in (p value < 0.05) over baseline will be considered improvement.
- Incidence of Treatment-Emergent Adverse Events [ Time Frame: 3 months ]The total number of adverse events and serious adverse events will be recorded and enumerated for each study participant. Gentamicin in high doses is associated with ototoxicity and nephrotoxicity. Audiometry and creatinine clearance tests will be performed throughout the study to monitor for the emergence of any treatment-related adverse events. In addition, as this treatment may result in the production of a protein that is hasn't been present in the patient's system, commercial ELISA tests will be performed on serum samples to test for the emergence of circulating anti-laminin 332 antibodies. Adverse events include a decline of >15 dB on pure tone audiometry at 2 consecutive frequencies, creatinine clearance <60ml/min, presence of antibodies to laminin 332, and for IV gentamicin recipients, serum gentamicin peak levels above 40 ug/ml and trough levels above 2 ug/ml.
- Generation of new hemidesmosomes as assessed by electron microscopy. [ Time Frame: 3 months ]Any new hemidesmosomes detected by electron microscopy in post-treatment skin biopsies will be enumerated and compared to baseline.
- Improved wound closure. [ Time Frame: 3 months ]Participants in the Topical arm will treat and monitor specific test sites, along with untreated control sites, selected during their baseline visits. Photographs will be used to assess the size of open erosions. Wound areas (treated and untreated) (cm2) will be measured using computer-assisted planimetry of digital photographs taken throughout the study.
- Reduction in blistering [ Time Frame: 3 months ]Participants in the Topical arm will treat and monitor specific test sites, along with untreated control sites, selected during their baseline visits. Photographs and patient diaries will be used to assess the number of blisters that appear at the test sites as well as whether the wound had closed during treatment.

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.
Ages Eligible for Study: | Child, Adult, Older Adult |
Sexes Eligible for Study: | All |
Accepts Healthy Volunteers: | No |
Inclusion Criteria:
1. JEB patients with nonsense mutations in the LAMB3 gene in either one or two alleles.
Exclusion Criteria:
- JEB patients who do not have nonsense mutations in the LAMB3 gene in either allele.
- Pre-existing known auditory impairment.
- Pre-existing known renal impairment.
- Pre-existing known allergies to aminoglycosides or sulfate compounds.
- Pregnancy.

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.
Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT03526159
Contact: Mei Chen, Ph.D. | 3238650621 | chenm@usc.edu | |
Contact: David Woodley, M.D. | 3238650956 | dwoodley@usc.edu |
United States, California | |
University of Southern California | Recruiting |
Los Angeles, California, United States, 90033 | |
Contact: David Woodley, MD 323-865-0956 dwoodley@usc.edu | |
Contact: Mei Chen, Ph.D 323-865-0621 chenm@usc.edu |
Responsible Party: | David Woodley, Professor, University of Southern California |
ClinicalTrials.gov Identifier: | NCT03526159 |
Other Study ID Numbers: |
HS-18-00290 |
First Posted: | May 16, 2018 Key Record Dates |
Last Update Posted: | April 7, 2020 |
Last Verified: | April 2020 |
Studies a U.S. FDA-regulated Drug Product: | Yes |
Studies a U.S. FDA-regulated Device Product: | No |
Product Manufactured in and Exported from the U.S.: | No |
Herlitz Laminin 332 Laminin beta 3 JEB |
Epidermolysis Bullosa Epidermolysis Bullosa, Junctional Gentamicins Skin Abnormalities Congenital Abnormalities Skin Diseases, Genetic Genetic Diseases, Inborn |
Skin Diseases Skin Diseases, Vesiculobullous Anti-Bacterial Agents Anti-Infective Agents Protein Synthesis Inhibitors Enzyme Inhibitors Molecular Mechanisms of Pharmacological Action |